肾衰竭患者中使用RAS阻滞剂与COVID-19相关死亡风险的关系
该研究基于欧洲肾脏协会COVID-19数据库(ERACODA),纳入2020年2月至10月间459例肾移植受者和1052例透析患者,分析ACEI/ARB使用与28天死亡率的关系。结果显示,在肾移植受者和透析患者中,ACEI/ARB使用或停用均与28天死亡率无显著关联。
要点
- 肾移植受者和透析患者中,ACEI/ARB使用与28天死亡率无显著关联。
- 停用ACEI/ARB在调整COVID-19严重程度后与死亡率无显著关联。
- 亚组分析结果一致,未发现ACEI/ARB使用增加死亡风险。
核心结论
- 在肾移植受者和透析患者中,ACEI/ARB使用或停用与28天死亡率无显著关联。
研究设计与样本
- 基于ERACODA数据库,纳入2020年2月1日至10月1日期间459例肾移植受者和1052例透析患者,均有28天死亡率数据,使用Cox比例风险回归计算风险比。
主要发现
- 肾移植受者中,189例(41%)使用ACEI/ARB,88例(19%)在28天内死亡;透析患者中,288例(27%)使用ACEI/ARB,244例(23%)在28天内死亡。
- 肾移植受者中,ACEI/ARB使用与28天死亡率的调整风险比为1.12(95%CI 0.69-1.83);透析患者中为1.04(95%CI 0.73-1.47)。
- 肾移植受者中,停用ACEI/ARB在调整人口学和合并症后与较高死亡风险相关,但进一步调整COVID-19严重程度后不再显著(调整风险比1.36,95%CI 0.40-4.58);透析患者中停用与死亡率无关联。
- 亚组分析(ACEI和ARB分别分析)及次要结局(住院、ICU入住、需呼吸机支持)结果相似。
临床怎么用
- 对于合并COVID-19的肾移植受者和透析患者,不应仅因COVID-19而常规停用ACEI/ARB。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: There is concern about potential deleterious effects of angiotensin-converting enzyme inhibitors (ACEis) and angiotensin II receptor blockers (ARBs) in patients with coronavirus disease 2019 (COVID-19). Patients with kidney failure, who often use ACEis/ARBs, are at higher risk of more severe COVID-19. However, there are no data available on the association of ACEi/ARB use with COVID-19 severity in this population. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: From the European Renal Association COVID-19 database (ERACODA), we retrieved data on kidney transplant recipients and patients on dialysis who were affected by COVID-19, between February 1 and October 1, 2020, and had information on 28-day mortality. We used Cox proportional-hazards regression to calculate hazard ratios for the association between ACEi/ARB use and 28-day mortality risk. Additionally, we studied the association of discontinuation of these agents with 28-day mortality. RESULTS: We evaluated 1511 patients: 459 kidney transplant recipients and 1052 patients on dialysis. At diagnosis of COVID-19, 189 (41%) of the transplant recipients and 288 (27%) of the patients on dialysis were on ACEis/ARBs. A total of 88 (19%) transplant recipients and 244 (23%) patients on dialysis died within 28 days of initial presentation. In both groups of patients, there was no association between ACEi/ARB use and 28-day mortality in both crude and adjusted models (in transplant recipients, adjusted hazard ratio, 1.12; 95% confidence interval [95% CI], 0.69 to 1.83; in patients on dialysis, adjusted hazard ratio, 1.04; 95% CI, 0.73 to 1.47). Among transplant recipients, ACEi/ARB discontinuation was associated with a higher mortality risk after adjustment for demographics and comorbidities, but the association was no longer statistically significant after adjustment for severity of COVID-19 (adjusted hazard ratio, 1.36; 95% CI, 0.40 to 4.58). Among patients on dialysis, ACEi/ARB discontinuation was not associated with mortality in any model. We obtained similar results across subgroups when ACEis and ARBs were studied separately, and when other outcomes for severity of COVID-19 were studied, e.g., hospital admission, admission to the intensive care unit, or need for ventilator support. CONCLUSIONS: Among kidney transplant recipients and patients on dialysis with COVID-19, there was no significant association of ACEi/ARB use or discontinuation with mortality.
引用
- Soler MJ, Noordzij M, Abramowicz D, et al. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure. Clin J Am Soc Nephrol. 2021. PMID: 34088718. doi:10.2215/CJN.18961220
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。